Introduction
============

Liver cancer is one of the most aggressive malignancies and one of the major causes of cancer death globally ([@ref-3]). Hepatocellular carcinoma (HCC) accounts for 75--85% of primary liver cancer cases. Distant metastasis occurred often in patients with HCC, and lung is the most frequent location of extrahepatic metastasis comprising approximately 30--50% of cases ([@ref-20]; [@ref-26]; [@ref-24]; [@ref-1]). Patients with pulmonary metastasis (PM) from HCC have an awfully unfavorable prognosis. The median overall survival (OS) was 4.5 months and 5-year OS rate was only 2.5% for synchronous HCC with PM ([@ref-8]). With the progress of therapeutic strategies for primary liver lesion and metastatic lung lesion, the survival of HCC patients with PM has been improved significantly. Therefore, it is of importance to construct metastatic risk and survival prediction assessment approaches for clinical decision-making.

Several literature reported some predictors and prognostic factors for HCC patients with PM ([@ref-17]; [@ref-10]; [@ref-16]); however, it has not yet been well elucidated in population-based studies. This research aimed to identify risk factors causing PM from HCC and prognostic factors for HCC patients with PM at initial diagnosis on the basis of the Surveillance, Epidemiology, and End Results (SEER) database. Nomograms were also built as visualized tools for quantifying estimation of metastasis risk and OS.

Materials and Methods
=====================

Ethics statement
----------------

This research was exempted by the Ethics Committee of Zhongshan Hospital of Fudan University (Shanghai, China), because data extracted from the publicly available SEER database were recognized as nonhuman studies ([@ref-18]).

Patient selection
-----------------

We extracted patients' data from the SEER database (<http://seer.cancer.gov/>), which collected cancer information from population-based cancer registries covering nearly 30% of the US population. Because information about the variable CS mets at DX-lung, which indicated the presence or absence of PM, was not available before 2010, patients diagnosed with HCC between 2010 and 2015 were finally included in our research. Exclusion criteria were as follows: (1) patients whose pathological type was not HCC; (2) patients for whom liver cancer was not their first primary tumor; (3) patients without follow-up time; (4) patients without cause of death; (5) patients with unknown race, T stage, surgical approach, bone metastasis, brain metastasis, intrahepatic metastasis, and PM. The selection process and selection codes were shown in [Fig. 1](#fig-1){ref-type="fig"} and [Table S1](#supp-1){ref-type="supplementary-material"}. The old version was converted to the eighth American Joint Committee on Cancer (AJCC) TNM staging system, in which T stage reflects primary tumor size, number of primary lesions, and invasive structures of primary tumor, and N stage reflects metastasis of regional lymph nodes. The raw measurements of 30,641 patients diagnosed with HCC were provided in [Data S1](#supp-2){ref-type="supplementary-material"} and raw measurements of 1,732 HCC patients with PM were shown in [Data S2](#supp-3){ref-type="supplementary-material"}.

![The study flow diagram of the selection process.](peerj-07-7496-g001){#fig-1}

The variables sex, age at diagnosis, race, T stage, N stage, primary tumor size, alpha-fetoprotein (AFP), surgical approach, radiation, chemotherapy, bone metastasis, brain metastasis, intrahepatic metastasis, PM, and cause-specific death classification were used in our research. The surgical approaches toward primary intrahepatic tumor included local treatment and liver resection, and the local treatment referred to therapeutic modalities such as transarterial chemoembolization (TACE), radiofrequency ablation, and percutaneous ethanol injection. The primary survival outcomes of the present research were OS and cancer-specific survival (CSS).

Statistical analysis
--------------------

Statistical analyses were all conducted with SPSS 21.0 statistical software (SPSS Inc, Chicago, IL, USA) and R software version 3.5.2 ([@ref-28]). The Pearson χ^2^ test was applied to compare categorical variables between patients with and without PM. Multivariate logistic regression analysis was adopted to determine risk factors for PM from HCC. The OS and CSS curves were compared using the Kaplan--Meier method with the Log-rank test. Univariate and multivariate analyses were conducted by the Cox regression model, and those variables with statistical significance in univariate analysis were finally included into the multivariable analysis. Nomograms based on the results of multivariate logistic regression model and Cox regression model were built, and the efficiency of prediction was estimated by Harrell's C-index statistic and calibration curves using bootstrapping variable selection algorithms ([@ref-2]). All tests were two-sided, and *P*-values less than 0.05 were considered to be statistically significant.

Results
=======

Baseline characteristics of study population
--------------------------------------------

As shown in [Fig. 1](#fig-1){ref-type="fig"}, a total of 30,641 patients diagnosed with HCC were included in our research, of whom 1,732 cases (5.7%) were with PM at initial diagnosis and 28,909 cases (94.3%) were without. The median follow-up time of the entire study cohort was 8 months (interquartile range, 2--21 months). The median follow-up time for patients with and without PM were 1 month (interquartile range, 0--3 months) and 9 months (interquartile range, 2--22 months), respectively. The 1-, 2-, and 3-year OS for all patients were 50.5%, 36.2%, and 28.0%, while they were 9.3%, 4.5%, and 2.4% for patients with PM, and 53.0%, 38.1%, and 29.5% for those without PM. [Table 1](#table-1){ref-type="table"} showed the clinical and pathological features of the population study. [Figure 2](#fig-2){ref-type="fig"} showed the significantly shorter OS and CSS of the patients with PM from HCC, and a sudden decline of the survival curve in the first 12 months.

![Survival analysis for hepatocellular carcinoma patients with and without pulmonary metastasis.\
(A) Kaplan--Meier survival curves of overall survival for hepatocellular carcinoma patients with and without pulmonary metastasis. (B) Kaplan--Meier survival curves of cancer-specific survival for hepatocellular carcinoma patients with and without pulmonary metastasis.](peerj-07-7496-g002){#fig-2}
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###### Clinical and pathological features of 30,641 patients diagnosed with hepatocellular carcinoma.
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  --------------------------------------------------------------------------------------------------
  Variable                  Without pulmonary metastasis\   With pulmonary metastasis\   *P*-value
                            number (%)                      number (%)                   
  ------------------------- ------------------------------- ---------------------------- -----------
  Sex                                                                                    0.192

    Male                    22,411 (77.5)                   1,366 (78.9)                 

    Female                  6,498 (22.5)                    366 (21.1)                   

  Age (year)                                                                             \<0.001

    ≤50                     2,229 (7.7)                     186 (10.7)                   

    \>50                    26,680 (92.3)                   1,546 (89.3)                 

  Race                                                                                   \<0.001

    White                   20,042 (69.3)                   1,086 (62.7)                 

    Black                   4,038 (14.0)                    304 (17.6)                   

    Other                   4,829 (16.7)                    342 (19.7)                   

  T stage                                                                                \<0.001

    T1                      12,645 (43.7)                   370 (21.4)                   

    T2                      6,370 (22.0)                    155 (8.9)                    

    T3                      3,709 (12.8)                    349 (20.2)                   

    T4                      3,834 (13.3)                    488 (28.2)                   

    Tx                      2,351 (8.1)                     370 (21.4)                   

  N stage                                                                                \<0.001

    N0                      25,320 (87.6)                   1,101 (63.6)                 

    N1                      1,829 (6.3)                     337 (19.5)                   

    Nx                      1,760 (6.1)                     294 (17.0)                   

  Surgery                                                                                \<0.001

    No surgery              21,628 (74.8)                   1,697 (98.0)                 

    Local treatment         3,185 (11.0)                    14 (0.8)                     

    Liver resection         4,096 (14.2)                    21 (1.2)                     

  Radiation                                                                              0.151

    No                      28,585 (98.9)                   1,719 (99.2)                 

    Yes                     324 (1.1)                       13 (0.8)                     

  Chemotherapy                                                                           \<0.001

    No                      16,284 (56.3)                   1,131 (65.3)                 

    Yes                     12,645 (43.7)                   601 (34.7)                   

  Tumor size (cm)                                                                        \<0.001

    ≤5                      15,327 (53.0)                   278 (16)                     

    \>5                     10,040 (34.7)                   934 (53.9)                   

    Unknown                 3,542 (12.3)                    520 (30.0)                   

  AFP                                                                                    

    Normal                  6,287 (21.7)                    162 (9.4)                    \<0.001

    Elevated                17,075 (59.1)                   1,200 (69.3)                 

    Unknown                 5,547 (19.2)                    370 (21.4)                   

  Bone metastasis                                                                        \<0.001

    No                      27,941 (96.7)                   1,442 (83.3)                 

    Yes                     968 (3.3)                       290 (16.7)                   

  Brain metastasis                                                                       \<0.001

    No                      28,858 (99.8)                   1,693 (97.7)                 

    Yes                     51 (0.2)                        39 (2.3)                     

  Intrahepatic metastasis                                                                \<0.001

    No                      28,738 (99.4)                   1,567 (90.5)                 

    Yes                     171 (0.6)                       165 (9.5)                    
  --------------------------------------------------------------------------------------------------

**Note:**

AFP, alpha-fetoprotein.

Predictors for pulmonary metastasis
-----------------------------------

As shown in [Table 2](#table-2){ref-type="table"}, the multivariate logistic regression analysis revealed that younger age (*P* = 0.001), non-white race (*P* \< 0.001), higher T stage (*P* \< 0.001), higher N stage (*P* \< 0.001), larger primary tumor size (*P* \< 0.001), elevated AFP (*P* \< 0.001), and presence of bone (*P* \< 0.001), brain (*P* \< 0.001), and intrahepatic metastasis (*P* \< 0.001) were the potential significant predictors for PM from HCC.
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###### Multivariate logistic regression analysis of predictors of pulmonary metastasis from hepatocellular carcinoma.
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  Variable                  OR          95% CI              *P*-value
  ------------------------- ----------- ------------------- -----------
  Age (year)                                                0.001
    ≤50                     Reference                       
    \>50                    0.756       \[0.637--0.896\]    0.001
  Race                                                      \<0.001
    White                   Reference                       
    Black                   1.245       \[1.083--1.433\]    0.002
    Other                   1.349       \[1.180--1.542\]    \<0.001
  T stage                                                   \<0.001
    T1                      Reference                       
    T2                      1.172       \[0.955--1.438\]    0.128
    T3                      1.320       \[1.113--1.567\]    0.001
    T4                      1.878       \[1.607--2.194\]    \<0.001
    Tx                      1.788       \[1.471--2.173\]    \<0.001
  N stage                                                   \<0.001
    N0                      Reference                       
    N1                      2.184       \[1.891--2.522\]    \<0.001
    Nx                      1.971       \[1.683--2.308\]    \<0.001
  Tumor size (cm)                                           \<0.001
    ≤5                      Reference                       
    \>5                     3.321       \[2.807--3.930\]    \<0.001
    Unknown                 3.722       \[3.054--4.535\]    \<0.001
  AFP                                                       \<0.001
    Normal                  Reference                       
    Elevated                1.829       \[1.536--2.178\]    \<0.001
    Unknown                 1.535       \[1.255--1.877\]    \<0.001
  Bone metastasis                                           \<0.001
    No                      Reference                       
    Yes                     2.976       \[2.542--3.483\]    \<0.001
  Brain metastasis                                          \<0.001
    No                      Reference                       
    Yes                     6.906       \[4.287--11.126\]   \<0.001
  Intrahepatic metastasis                                   \<0.001
    No                      Reference                       
    Yes                     7.743       \[6.087--9.850\]    \<0.001

**Note:**

OR, odd ratio; CI, confidence interval; AFP, alpha-fetoprotein.

A nomogram for metastasis risk assessment was built on the basis of the results of multivariate logistic regression analysis above excluding surgical approach and chemotherapy which were obviously not the risk factors for PM from HCC ([Fig. 3](#fig-3){ref-type="fig"}). It had a Harrell's C-index statistic of 0.768, indicating a good predictive ability for risk of PM from HCC.

![Nomogram to predict pulmonary metastasis from hepatocellular carcinoma.](peerj-07-7496-g003){#fig-3}

Prognostic factors for pulmonary metastasis
-------------------------------------------

As shown in [Table 3](#table-3){ref-type="table"}, univariate Cox regression analysis indicated age (*P* = 0.049), T stage (*P* = 0.020), surgical approach (*P* \< 0.001), chemotherapy (*P* \< 0.001), and primary tumor size (*P* \< 0.001) as prognostic factors for HCC patients with PM at initial diagnosis. Multivariate Cox regression analysis based on the results above revealed that older age (*P* = 0.014), higher T stage (*P* = 0.009), absence of surgery toward primary liver lesion (*P* \< 0.001), absence of chemotherapy (*P* \< 0.001) were associated with a worse prognosis for HCC patients with PM.
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###### Univariate and multivariate Cox regression analyses of overall survival for patients with pulmonary metastasis from hepatocellular carcinoma.
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  Variable                  Univariate   Multivariate                                                
  ------------------------- ------------ ------------------ --------- ----------- ------------------ ---------
  Sex                                                       0.149                                    
    Male                    Reference                                                                
    Female                  0.913        \[0.807--1.033\]   0.149                                    
  Age (year)                                                0.049                                    0.014
    ≤50                     Reference                                 Reference                      
    \>50                    1.176        \[1.001--1.382\]   0.049     1.228       \[1.042--1.446\]   0.014
  Race                                                      0.987                                    
    White                   Reference                                                                
    Black                   1.011        \[0.886--1.154\]   0.873                                    
    Other                   1.002        \[0.881--1.140\]   0.974                                    
  T stage                                                   0.020                                    0.009
    T1                      Reference                                 Reference                      
    T2                      1.039        \[0.854--1.264\]   0.703     1.135       \[0.916--1.407\]   0.247
    T3                      1.118        \[0.958--1.305\]   0.156     1.222       \[1.036--1.441\]   0.017
    T4                      1.230        \[1.065--1.420\]   0.005     1.277       \[1.105--1.477\]   0.001
    Tx                      1.239        \[1.062--1.446\]   0.006     1.043       \[0.880--1.236\]   0.628
  N stage                                                   0.088                                    
    N0                      Reference                                                                
    N1                      1.141        \[1.005--1.297\]   0.042                                    
    Nx                      1.094        \[0.956--1.252\]   0.194                                    
  Tumor size (cm)                                           \<0.001                                  0.085
    ≤5                      Reference                                 Reference                      
    \>5                     1.110        \[0.964--1.279\]   0.148     1.104       \[0.930--1.309\]   0.258
    Unknown                 1.340        \[1.149--1.564\]   \<0.001   1.229       \[1.019--1.482\]   0.031
  AFP                                                       0.129                                    
    Normal                  Reference                                                                
    Elevated                1.191        \[1.001--1.415\]   0.048                                    
    Unknown                 1.199        \[0.987--1.458\]   0.068                                    
  Bone metastasis                                           0.654                                    
    No                      Reference                                                                
    Yes                     0.970        \[0.851--1.107\]   0.654                                    
  Brain metastasis                                          0.653                                    
    No                      Reference                                                                
    Yes                     1.078        \[0.778--1.494\]   0.653                                    
  Intrahepatic metastasis                                   0.794                                    
    No                      Reference                                                                
    Yes                     1.023        \[0.863--1.212\]   0.794                                    
  Surgery                                                   \<0.001                                  \<0.001
    No surgery              Reference                                 Reference                      
    Local treatment         0.386        \[0.213--0.700\]   0.002     0.465       \[0.255--0.847\]   0.012
    Liver resection         0.292        \[0.161--0.530\]   \<0.001   0.319       \[0.175--0.580\]   \<0.001
  Radiation                                                 0.166                                    
    No                      Reference                                                                
    Yes                     0.644        \[0.346--1.200\]   0.166                                    
  Chemotherapy                                              \<0.001                                  \<0.001
    No                      Reference                                 Reference                      
    Yes                     0.481        \[0.432--0.536\]   \<0.001   0.478       \[0.428--0.534\]   \<0.001

**Note:**

HR, hazard ratio; CI, confidence interval; AFP, alpha-fetoprotein.

A prognostic nomogram on the basis of the results of multivariate analysis above was constructed ([Fig. 4](#fig-4){ref-type="fig"}), which internally validated by bootstrapping in 1,000 bootstrap samples. It had a Harrell's C-index statistic of 0.687 (95% CI \[0.670--0.703\]), again showing a good predictive efficiency for OS of HCC patients with newly diagnosed PM. As shown in [Fig. S1](#supp-4){ref-type="supplementary-material"}, the calibration curves for the probability of 1-, 2-, and 3-year OS also indicated a good consistency with the actual survival.

![Nomogram to predict 1-, 2-, and 3-year overall survival of patients with pulmonary metastasis from hepatocellular carcinoma.](peerj-07-7496-g004){#fig-4}

Discussion
==========

Hepatocellular carcinoma is a highly invasive tumor, which is prone to distant metastasis. Meanwhile, with the development of screening modalities, more and more extrahepatic metastases have been detected. Lung is the most common site of distant metastases and prognosis of HCC patients with PM was extremely poor ([@ref-22]; [@ref-12]; [@ref-23]; [@ref-8]). Our research revealed that median OS of patients with PM from HCC at initial diagnosis was 1 months and 1-, 2-, and 3-year OS rate were 9.3%, 4.5%, and 2.4%, which was consistent with the results reported in the previous literature. Despite poor prognosis of HCC patients with PM, it was believed that well-control of primary liver lesion plus treatment for pulmonary lesion such as pulmonary metastasectomy could prolong survival time of these patients ([@ref-13]; [@ref-21]; [@ref-14]; [@ref-9]). Therefore, exploring predictors of PM from HCC appears to be necessary for clinical decision-making. [@ref-27] reported that T stage, N stage, brain metastasis, and intrahepatic metastasis were risk factors for bone metastasis from HCC. [@ref-6] pointed out that bone metastasis was significantly associated with brain metastasis from HCC. Besides, positive AFP, bilobar HCC lesions, multiplicity of HCC lesions, and primary tumor size ≥5 cm at initial diagnosis were also the independent predictors for distant metastases of HCC ([@ref-16]; [@ref-7]; [@ref-5]; [@ref-4]). These indicators reflected the invasiveness of primary tumor and this was an explanation that these indicators were risk factors for extrahepatic metastases from HCC. In our research, we concluded that younger age, non-white race, larger primary tumor size, higher T stage, higher N stage, elevated AFP, and presence of bone, brain and intrahepatic metastasis were significant predictors for PM from HCC.

Our research further showed that HCC patients having PM with older age, higher T stage, absence of surgery for primary intrahepatic lesion, or absence of chemotherapy significantly had an unfavorable prognosis. On the basis of the eighth edition of AJCC staging system for liver cancer, primary tumor size is an important reference criterion for T staging of HCC. [@ref-10] identified intrahepatic tumor size as a major prognostic factor for HCC patients with PM undergoing liver transplantation. [@ref-17] also revealed that primary tumor size was independent prognostic factor for PM of HCC patients following hepatectomy. However, the T stage, which contains not only information about tumor size but also vascular invasion and number of primary tumor lesions, was more relevant to prognosis of patients than the indicator primary tumor size itself based on the AJCC staging system. [@ref-8] showed that primary tumor size was not a prognostic factor while the T stage was in univariate analysis for OS in synchronous HCC and PM patients, although T stage did not achieve statistically significance in multivariate analysis. In our research, we found that the T stage was significantly related to OS of HCC patients with newly diagnosed PM, while primary tumor size was not. The higher T stage indicated a stronger ability of invasion and metastasis of tumor, and it might be the reason why the higher T stage led to worse prognosis.

To date, there are no standard treatment for HCC patients with PM. Because of the presence of distant metastasis, these patients lose the chance for radical surgery for primary intrahepatic tumor. However, it is widely recognized that better-control of primary HCC lesion contributes to a longer survival time. With the progress of surgical approaches, such as TACE, percutaneous ethanol injection, radiofrequency ablation, hepatectomy and liver transplantation, the control of primary HCC lesion have been improved and survival time has also been significantly prolonged for these patients. [@ref-9] indicated that HCC patients with PM undergoing pulmonary metastasectomy treated with supportive care had a significantly worse prognosis than those received liver resection, TACE or radiofrequency ablation. [@ref-15] reported that compared with local treatment, liver resection contributed to the prolongation of survival of HCC patients with PM undergoing pulmonary metastasectomy. [@ref-8] revealed that HCC patients with PM at initial diagnosis undergoing liver resection survived longer than those treated with TACE or ablation. Although patient populations were different in these studies, it still demonstrated that well-control of primary HCC lesion improved survival of HCC patients with PM. Our research supported the results above, showing that surgical approach had the greatest impact on the prognosis and HCC patients with newly diagnosed PM benefited most from liver resection compared with local treatment or no surgery performed. Hence, we concluded that liver resection was a better treatment modality for HCC patients with PM who were suitable for the aggressive surgery.

There is no final conclusion as to whether patients with PM from HCC can benefit from chemotherapy, and current studies are mostly case reports with a small sample size. Several prospective studies showed that appropriate chemotherapy regimens could alleviate the patients' condition. In a clinical trial which comprised 71% of cases with PM from HCC, [@ref-11] revealed that FMP chemotherapy modality (a combined treatment of 5-fluorouracil, mitoxantrone, and cisplatin) had remarkable antineoplastic activity for patients with distant metastases. [@ref-19] reported that chemotherapy of S-1 (a prodrug of 5-fluorouracil) and interferon-alpha contributed to the clinical remission of HCC with extrahepatic metastasis. [@ref-25] also demonstrated that S-1/interferon-alpha chemotherapy modality was suitable and benefit for patients with distant metastases from HCC, especially those with PM. Due to lack of control group without chemotherapy, these studies were not able to explain the role of chemotherapy in prolonging survival of patients. However, we noted that the improvement of clinical response rate caused by chemotherapy offered patients greater opportunity to receive surgery which was believed to prolong OS. In the present research, it was obvious that patients with PM from HCC who received chemotherapy survived longer. Unfortunately, because of no information about detailed chemotherapy strategies in our data set, we were not able to compare the impact of different chemotherapy regimens on survival.

To facilitate clinical application, we established two nomograms for risk assessment of PM from HCC and survival prediction of HCC patients with PM at initial diagnosis. Both models had satisfactory predictive abilities and could be convenient individualized predictive tools for clinical decision-making. We recommended a close monitoring including detection of tumor markers and regular chest computed tomography examination for HCC patients with age less than 50 year old, non-white race, larger primary tumor size, higher T stage, higher N stage, elevated AFP, and presence of bone, brain and intrahepatic metastasis at initial diagnosis to help early detection of PM and to determine the therapeutic modalities earlier. Although there is no evidence that early detection of PM from HCC contributes to prolonging survival, we believes that early detection can be beneficial for patients as it helps management of disease and survival prediction. For HCC patients with newly diagnosed PM, we suggested aggressive therapies involving surgery toward the intrahepatic tumor or chemotherapy for highly selective patients with appropriate physical conditions and other favorable factors.

To our knowledge, this was the first population-based research focusing on the construction of metastatic risk and survival prediction approaches for patients with PM from HCC at initial diagnosis. However, limitations of the present work should be noted. Firstly, this was a retrospective study in which selection bias existed inevitably. Secondly, information about detailed treatment modalities for primary intrahepatic lesion and metastatic pulmonary lesion was not available in the SEER database and the information about pathological variable primary tumor grade was unknown in nearly 70% of the entire cohort, which was important for the multivariate analysis. Thirdly, information about performance status could not be obtained from the SEER database, which influenced therapeutic decision-making and might be a confounding factor in this study. Finally, the two nomograms we built were not validated using an external validation cohort and a further research is needed to verify our nomograms in the future.

Conclusions
===========

For patients with HCC, age, race, T stage, N stage, primary tumor size, AFP, and bone, brain and intrahepatic metastasis were the risk factors of PM. For patients with PM from HCC at initial diagnosis, Age, T stage, surgical approach and chemotherapy were independent prognostic factors for OS. Nomograms we built may be individual and convenient tools for metastatic risk and prognostic assessment for PM from HCC.
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\(A\) Calibration curves of the nomogram prediction of 1-year overall survival of patients with pulmonary metastasis from hepatocellular carcinoma. (B) Calibration curves of the nomogram prediction of 2-year overall survival of patients with pulmonary metastasis from hepatocellular carcinoma. (C) Calibration curves of the nomogram prediction of 3-year overall survival of patients with pulmonary metastasis from hepatocellular carcinoma.
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